Topic: glioblastoma multiforme (GBM)
Blocking the immune-suppressing enzyme CD73 in mouse models of glioblastoma improved survival among animals given checkpoint inhibitors.
After AbbVie’s Depatux-M and Bristol-Myers Squibb’s Opdivo failed to make the grade in brain cancer, Tocagen was left as one of the last companies with a late-stage program in the cancer, but in September, it revealed that its Toca 511/Toca FC gene therapy was also a bust.
2019 was something of an annus horribilis when it came to trying to find new therapies for aggressive brain cancer glioblastoma multiforme, and one of the biggest disappointments came from the failure of an immuno-oncology approach to the disease.
High-grade gliomas are one of the toughest tumors to treat, and the first entrant on our alphabetical list—AbbVie’s antibody-drug conjugate Depatux-M—is one of at least three drugs that failed to hit the mark in this highly aggressive form of brain cancer in 2019.
This year’s top 15 list has been drawn up to include trials whose failure we judge to have had material consequences on their sponsors and the patients for whom the drugs are being developed. The catalog includes multiple trials for aggressive brain cancer, Alzheimer’s disease, nonalcoholic steatohepatitis and heart disease.
After steering Spark's Luxturna through FDA approval and launch, COO John Furey is heading Imvax, which is developing a brain cancer vaccine.
A Cedars-Sinai team used a polymer scaffold to deliver two types of immune checkpoint inhibitors in mouse models of glioblastoma.
A phase 1 clinical trial of Ziopharm's IL-12 gene therapy and a production "switch" shows promise in recurrent glioblastoma.
A new partnership will test drug cocktails containing Karyopharm's new product Xpovio in cell samples from glioblastoma patients.
The deal will give Merck control of an experimental oral HIF-2α inhibitor that may challenge Keytruda for the metastatic renal cell carcinoma market.